By: Maribel Yoo On: April 19, 2017 In: Nexus Strategy, Portfolio Comments: 0

Cage Pharma  ( is a bio-pharmaceutical company focused on the development of new drugs targeting the metabolism of tumors.  Cage’s lead compound, PS-102, is an innovative and patented formulation of a compound that has been tested in numerous animal models and in limited human trials (through compassionate use protocols), where it has shown very high efficacy and tolerability. The data suggests that PS-102 will be effective against most, if not all, types of cancers, including pancreatic, lung, and breast cancer, because it attacks a fundamental component of the metabolic pathway of tumors. Cage Pharma already holds an IND for PS-101 and anticipates submitting a new IND application for PS-102 in early 2018.

Deal Source

Dr. Bert Vogelstein

Board Representation

George Petrocheilos

R. Jacob Vogelstein